Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Early-life peripheral infections reprogram retinal microglia and aggravate neovascular age-related macular degeneration in later life
Masayuki Hata, … , Ariel M. Wilson, Przemyslaw Sapieha
Masayuki Hata, … , Ariel M. Wilson, Przemyslaw Sapieha
Published February 15, 2023
Citation Information: J Clin Invest. 2023;133(4):e159757. https://doi.org/10.1172/JCI159757.
View: Text | PDF
Research Article Ophthalmology

Early-life peripheral infections reprogram retinal microglia and aggravate neovascular age-related macular degeneration in later life

  • Text
  • PDF
Abstract

Pathological neovascularization in age-related macular degeneration (nvAMD) drives the principal cause of blindness in the elderly. While there is a robust genetic association between genes of innate immunity and AMD, genome-to-phenome relationships are low, suggesting a critical contribution of environmental triggers of disease. Possible insight comes from the observation that a past history of infection with pathogens such as Chlamydia pneumoniae, or other systemic inflammation, can predispose to nvAMD in later life. Using a mouse model of nvAMD with prior C. pneumoniae infection, endotoxin exposure, and genetic ablation of distinct immune cell populations, we demonstrated that peripheral infections elicited epigenetic reprogramming that led to a persistent memory state in retinal CX3CR1+ mononuclear phagocytes (MNPs). The immune imprinting persisted long after the initial inflammation had subsided and ultimately exacerbated choroidal neovascularization in a model of nvAMD. Single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) identified activating transcription factor 3 (ATF3) as a central mediator of retina-resident MNP reprogramming following peripheral inflammation. ATF3 polarized MNPs toward a reparative phenotype biased toward production of proangiogenic factors in response to subsequent injury. Therefore, a past history of bacterial endotoxin–induced inflammation can lead to immunological reprograming within CNS-resident MNPs and aggravate pathological angiogenesis in the aging retina.

Authors

Masayuki Hata, Maki Hata, Elisabeth M.M.A. Andriessen, Rachel Juneau, Frédérique Pilon, Sergio Crespo-Garcia, Roberto Diaz-Marin, Vera Guber, Francois Binet, Frédérik Fournier, Manuel Buscarlet, Caroline Grou, Virginie Calderon, Emilie Heckel, Heather J. Melichar, Jean-Sebastien Joyal, Ariel M. Wilson, Przemyslaw Sapieha

×

Figure 9

Peripheral exposure to endotoxins modulates myeloid cell response via ATF3 deregulation.

Options: View larger image (or click on image) Download as PowerPoint
Peripheral exposure to endotoxins modulates myeloid cell response via AT...
(A) Volcano plot of accessible regions with differentially accessible regions (DARs; defined by an FDR adjusted P value < 0.05, total of 51 DARs) identified between comparisons of microglial 4×LPS cluster (C3) versus microglial PBS cluster (C2) as found by CX3CR1+ retinal myeloid cell scATAC-seq data. (B) Cis-coaccessibility network (CCAN) links between the ATF3 promoter and distal sites in the surrounding region generated by subset analysis by cluster. Connections from microglial PBS cluster (C2) and microglial 4×LPS cluster (C3) are shown, with a minimum coaccessibility score of 0.3. (C) Chromatin accessibility in the promoter region of Atf3 in BMDMs from PBS-pretreated and 4×LPS-pretreated mice as analyzed by qPCR. n = 4 (PBS), n = 4 (4×LPS). (D) Representative immunoblots showing p-NF-κB, total NF-κB, p-c-JUN, total c-JUN, and ATF3 expression in BMDMs from PBS-pretreated and 4×LPS-pretreated mice with and without LPS restimulation. (E) Schematic representation of knockdown of Atf3 gene expression in BMDMs using siRNA. C57BL/6J mice were treated with 4×LPS or PBS at 7 weeks of age and BM cells were collected at 11 weeks of age. BM cells were differentiated into BMDMs with M-CSF. BMDMs were transfected with Atf3 or control siRNA for 24 hours and then restimulated with LPS for 4 hours. RNA was extracted for qPCR analysis. (F–J) mRNA expression in BMDMs transfected with Atf3 or control siRNA from PBS-pretreated and 4×LPS-pretreated mice with LPS restimulation: Atf3 (F), Tnf (G), Il6 (H), Vegfa (I), and Pdgfb (J); n = 6 for all groups. Data are presented as mean ± SEM. Comparisons between groups were analyzed using Student’s unpaired t test (C) or 1-way ANOVA with Tukey’s multiple-comparison test (F–J). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts